Gedif K - Search Results

1

Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.

Sadda S, Sarraf D, Khanani AM, Tadayoni R, Chang AA, Saffar I, Gedif K, Wong DT. Sadda S, et al. Among authors: gedif k. Br J Ophthalmol. 2024 May 21;108(6):852-858. doi: 10.1136/bjo-2023-323577. Br J Ophthalmol. 2024. PMID: 37669850 Free PMC article. Clinical Trial.

2

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.

Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, Lee WK, Chang AA, Monés J, D'Souza D, Weissgerber G, Gedif K, Koh A. Ogura Y, et al. Among authors: gedif k. Br J Ophthalmol. 2022 Jul;106(7):994-999. doi: 10.1136/bjophthalmol-2021-319090. Epub 2021 Jul 22. Br J Ophthalmol. 2022. PMID: 34301613 Free PMC article. Clinical Trial.

3

Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data.

Jhaveri C, Wykoff CC, Khanani AM, Eandi CM, Chang A, B G, Gedif KA, Singer M. Jhaveri C, et al. Among authors: gedif ka. Am J Ophthalmol. 2022 Apr;236:12-19. doi: 10.1016/j.ajo.2021.10.017. Epub 2021 Oct 22. Am J Ophthalmol. 2022. PMID: 34695400 Free article.

4

HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG. Dugel PU, et al. Among authors: gedif k. Ophthalmology. 2021 Jan;128(1):89-99. doi: 10.1016/j.ophtha.2020.06.028. Epub 2020 Jun 20. Ophthalmology. 2021. PMID: 32574761 Free article. Clinical Trial.

5

Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.

Singer M, Khanani AM, Wolf A, Flores R, Chhablani J, B G, Clemens A, Gedif K, Liu X, Mulyukov Z, Querques G. Singer M, et al. Among authors: gedif k. Ophthalmologica. 2022;245(4):315-322. doi: 10.1159/000524245. Epub 2022 Mar 28. Ophthalmologica. 2022. PMID: 35344964 Free article. Clinical Trial.

6

Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.

Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Lally DR, et al. Among authors: gedif k. Eye (Lond). 2023 Apr;37(6):1242-1248. doi: 10.1038/s41433-022-02092-5. Epub 2022 May 21. Eye (Lond). 2023. PMID: 35597816 Free PMC article.

7

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER.

Tadayoni R, Jaffe GJ, Holz FG, Schmidt-Erfurth U, Takahashi K, Cheung CMG, Hariprasad SM, Gedif K, Olsen R, Best C, Igwe F, Kaiser PK. Tadayoni R, et al. Among authors: gedif k. Ophthalmol Ther. 2023 Aug;12(4):2209-2216. doi: 10.1007/s40123-023-00735-8. Epub 2023 Jun 9. Ophthalmol Ther. 2023. PMID: 37294524 Free PMC article.

8

Correction: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.

Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Lally DR, et al. Among authors: gedif k. Eye (Lond). 2023 Jun;37(8):1748. doi: 10.1038/s41433-022-02130-2. Eye (Lond). 2023. PMID: 35676464 Free PMC article. No abstract available.

9

Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.

Regillo C, Singh R, Hamilton R, Gedif K, Best C, Koh A, Holz FG. Regillo C, et al. Among authors: gedif k. Ophthalmologica. 2022;245(5):403-412. doi: 10.1159/000524096. Epub 2022 Apr 25. Ophthalmologica. 2022. PMID: 35468601 Free article. Clinical Trial.

10

Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.

Singh RP, Jhaveri C, Wykoff CC, Gale RP, Staurenghi G, Iida T, Koh A, B G, Gedif K, Singer M. Singh RP, et al. Among authors: gedif k. Ophthalmol Retina. 2022 May;6(5):377-386. doi: 10.1016/j.oret.2021.12.014. Epub 2021 Dec 27. Ophthalmol Retina. 2022. PMID: 34968756 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters